A new paradigm for managing dyslipidemia with combination therapy: Laropiprant + niacin + simvastatin

Expert Opinion on Investigational Drugs

Volumn 19, Issue 3, 2010, Pages 437-449

  Yiu, Kai Hang ^a   Cheung, Bernard M Y ^a   Tse, Hung Fat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular disease; Laropiprant; Niacin; Simvastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PLACEBO; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MYALGIA; MYOPATHY; REVIEW; SIDE EFFECT;

ANTILIPEMIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; NIACIN; SIMVASTATIN;

EID: 76949084798     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003623223     Document Type: Review

References (62)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-1757
2. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435
3. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
4. Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-2497.
5. Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J Intern Med 2008;263:353-365
6. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310
7. Faergeman O, Holme I, Fayyad R, et al. Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009;104:459-463
8. Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79(1):8-15
9. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114
10. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381
11. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255
12. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592
13. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006;17:631-636
14. Kos Pharmaceuticals (currently) Abbott Pharmaceuticals DN1628V4-simcor-021408 Prescribing Information 2008
15. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-534
16. Kamal-Bahl SJ, Burke TA, Watson DJ, Wentworth CE. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin 2008;24:1817-1821
17. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009;63:1369-1377
18. Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-596
19. Dunn RT, Ford MA, Rindone JP, et al. Low-Dose Aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2:478-480
20. Thakkar RB, Kashyap ML, Lewin AJ, et al. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs 2009;9:69-79
21. Cheng K, Wu T-J, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006;103:6682-6687
22. Sturino CF, O'Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy-clopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007;50:794-806
23. Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subType 1. Clin Pharmacol Ther 2007;81:849-857
24. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-630
25. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study). Am J Cardiol 2008;101:1428-1436
26. Ballantyne CM, Davidson MH, McKenney JM, et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvstatin 80 mg montherapy: the SEACOAST II (high dose) study. J Clin Lipidol 2008;2:79-90
27. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8:69-81
28. Kos Pharmaceuticals (currently) Abbott Pharmaceuticals DN1628V4-simcor-021408 Prescribing Information 2008
29. Cayman Chemical. MK0524 product information. Copyright. Available from: http://www.caymanchem.com/pdfs/10009835.pdf. [Accessed 22 April 2009]
30. Plosker GL, McTavish D. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995 50:334-363
31. van Wijk JPH, Buirma R, van Tol A, et al. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis 2005;178:147-155
32. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-1845
33. Jin F-Y, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999;19:1051-1059
34. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2007;83:840-847
35. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6:313-325
36. Shichijo M, Arimura A, Hirano Y, et al. A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep. Clin Exp Allergy 2009;39:1404-1414
37. Moreland RB, Nehra A, Kim NN, et al. Expression of functional prostaglandin D (DP) receptors in human corpus cavernosum smooth muscle. Int J Impot Res 2002;14:446-452
38. Huang ZL, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 2007;7:33-38
39. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103:147-166
40. Rodinson JG. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vasc Health Risk Manag 2009;5:31-43
41. Pandian A, Arora A, Sperling LS, Khan BV. Targeting multiple dyslipidemias with fixed combinations-focus on extended release niacin and simvastatin. Vasc Health Risk Manag 2008;4:1001-1009
42. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-677
43. Karanam B, Madeira M, Bradley S, et al. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Drug Metab Dispos 2007;35:1196-1202
44. Airan-Javia SL, Wolf RL, Wolfe ML, et al. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low-and high-dose simvastatin monotherapy. Am Heart J 2009;157:687.e1-8
45. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-1970
46. Gleim G, Ballantyne CM, Liu N, et al. Efficacy and safety profile of coadministered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009;16:90-97
47. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-630
48. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
49. Kush D, Hu DY, Ye P, et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in asian lipid clinic patients. Cardiology 2009;114:192-198
50. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009;49:416-422
51. Kamal-Bahl S, Watson DJ, Ambegaonkar BM. Patients' experiences of niacin-induced flushing in clinical practice: A structured telephone interview. Clin Ther 2009;31:130-140
52. Wang W, Basinger A, Neese RA, et al. Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab 2000;279:E50-59
53. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99:S22-31
54. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-197
55. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT Study: a randomized trial. JAMA 2000;284:1263-1270
56. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-257
57. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006;97:477-479
58. Merck and Co. Zocor (simvastatin) [prescribing information]. Available from: http://www.merck.com/product/usa/pi-circulars/z/zocor/zocor-pi.pdf. [Accessed June 2008]
59. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-564
60. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the US FDA adverse event reporting system). Am J Cardiol 2007;99:379-381
61. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443
62. A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant ClinicaTrials.gov [online], http://clinicatrials.gov/ct2/show/NCT00461630 (2007)